Safety and Tolerability of Ceftazidime-Avibactam for pediatric patients with suspected or confirmed infections

Inclusion Criteria

• 1) Written informed consent will be obtained from parent(s) or other legally acceptable representative(s), and informed assent from patient (if age appropriate) will be obtained
• 2) Male or female children ages ≥3 months to <18 years.
• 3) Hospitalized, receiving systemic antibiotic therapy for the treatment of a suspected or confirmed infection, and expected to require hospitalization until after the end of treatment (EOT) evaluations are completed.
• 4) If female and has reached menarche, or has reached Tanner stage 3 breast development (even if not having reached menarche), the patient is practicing appropriate birth control or is sexually abstinent.
• 5) Likely to survive the current illness or hospitalization.
• 6) Sufficient intravascular access (peripheral or central) to receive study drug.